US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.
MRV Research
Promising Outcomes Reported For a Personalized Vaccine Against Cutaneous Melanoma
A new study is utilizing personalized immunotherapy to target specific tumor-associated genomic changes in an effort to combat tumors formed during cutaneous melanoma. The dendritic cell vaccine is tailored to recognize each patient’s tumor, which is thought to be the driving force underlying its ability to proficiently stimulate the immune system.
Melanoma Excision Frequently Delayed in Medicare Population
One in five Medicare patients with melanoma waits more than 1.5 months after diagnosis to undergo surgery, according to a retrospective study from Yale researchers recently published in JAMA Dermatology.
Triple Therapy for Melanoma
The immunotherapy ipilimumab (Yervoy, Bristol-Myers Squibb), is currently approved for metastatic melanoma by the US Food and Drug Administration (FDA). The combination of two targeted oral agents, dabrafenib (Tafinlar, GlaxoSmithKline), a BRAF inhibitor, plus trametinib (Mekinist, GlaxoSmithKline), a MEK inhibitor, is also approved for metastatic melanoma, but only in those patients whose tumors harbor a BRAF V600 mutation.